Clinical Research Directory

Inclusion Criteria: 1. Patients with primary ITP, in need for first line treatment according to 2019 ITP consensus2. 2. Previously untreated patients. Patients who have already started first-line therapy because of life-threatening bleeding are admitted to the study if samples are collected within 24 hours of starting treatment. In such cases, as first-line treatment steroids and platelet transfusions would be preferable over high-dose IVIg. Treatment received before the collection of samples will be carefully documented. 3. Age ≥ 18 years 4. Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: 1\. Secondary ITP. Patients with ANA positivity without a diagnosis of SLE are admitted to the study. As far as patients with ITP and antiphospholipid antibodies positivity, those with triple positivity (anti-beta2glicoprotein antibodies, anti-cardiolipin antibodies, lupus anticoagulans positivity) are excluded.